CTOs on the Move

Quanterix

www.quanterix.com

 
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company`s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix` technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.quanterix.com
  • 900 Middlesex Turnpike
    Billerica, MA USA 01821
  • Phone: 617.301.9400

Executives

Name Title Contact Details
Joel Nichols
Senior Vice President Digital and Information Profile

Funding

Quanterix raised $46M on 03/23/2016
Quanterix raised $49.7M on 10/25/2019
Quanterix raised $287.5M on 02/08/2021

Similar Companies

Priovant Therapeutics

Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.

Micronics

Micronics is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambagon Therapeutics

Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. Ambagon’s platform approach will...

BioEnterprise Corporation

BioEnterprise Corporation is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Better Therapeutics

Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.